PPT-Capturing and Reporting Adverse Events in Clinical Research

OBJECTIVES Describe Adverse Events Risks and Problems that can Occur in H uman S ubjects R esearch C ompliance with Safety R eporting R egulations in Clinical Research Identify Current Systems of Patient Care and Patient Safety in Research . Data Safety Monitoring and Reporting . requirements. Brown Bag Series: Noon / First Tuesday of the Month. April 4. th. , 2017 - . Auditorium . B. Updates. . AAHRPP update. New initiatives: . Improving the . Reporting Requirements. Protocol References. Section. Title. 7.2. Safety-Related. Data Collection. 7.3. Expedited Adverse Event Reporting. Other References and Resources. 3. Manual for Expedited Reporting of Adverse Events to DAIDS (Version 2.0). Dee Blumberg, PhD. An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related . (21 CFR 312.32).. Adverse Events. An adverse event or suspected adverse reaction is considered “serious” if, in the view of . S. Percy Ivy, MD. Associate Chief, Senior Investigator. Investigational Drug Branch, National Cancer Institute. ivyp@ctep.nci.nih.gov. . National Cancer Institute. . National Cancer Institute. Acknowledgement. Acknowledgment to . Ms. Chun Geok Ying . for preparation of the core contents of this presentation. Outline. Why is safety practices important?. What is safety monitoring? . Safety Reporting. Clinical and Institutional Disclosure of Adverse Events to Patients Call 1 of 2 Delivered May 21, 2012 updated to reflect directive’s reissue (October 31, 2018) Sponsoring Offices: National Center for Ethics in Health Care MODULE 3 Adverse events following immunizationOverviewUnder recommended conditions all vaccines used in national immunization programmes are safe and e31ective if used correctly In practice however no 655 West 12th AvenueVancouver BC V5Z 4R4Tel 6047072548Fax 6047072515wwwbccdccaCommunicable Disease Control ManualChapter 2 Immunization PartAdverse Events Following ImmunizationCommunicable Disease C Problems, and Protocol Deviations. Kathleen O’Malley RN, BSN, CCRP. Manager of Education and Training. Jefferson Clinical Research Institute. Kathleen.omalley@jefferson.edu. 1. Learning Objectives: Adverse Events. Version 04 . Feb. 2021. In . this. . training course you will learn. What. is . pharmacovigilance. ?. What is the pharmacovigilance responsibility of the investigator in a clinical trial?. What is the pharmacovigilance responsibility of the sponsor in a clinical trial?. 2019 Spring. SAFETY of the SUBJECT. Safety of the Subject. Key definitions. Identifying, documenting and reporting. Investigator reporting responsibilities . How are research participants protected? . The initiative primarily set out to guide clinicians, mainly . rheumatologists, but also in some countries internists and immunologists, who have to play a pivotal role in developing with the oncologists a patient-centred approach to improve the diagnosis and the management of rheumatic immune-related adverse events (irAEs).. �� &#x/Att;¬he; [/;ott;&#xom ];&#x/BBo;&#xx [6;.44;i 3;.73; 8;.68;– 4; .76;& ];&#x/Sub;&#xtype;&#x /Fo;&#xoter;&#x /Ty;&#xpe /;&#xPagi;&#xnati Authors: . 1. Juliet Jokwiro, . 1. Nicole Chekudambune-Kawaza, . 1. Kenny Sithole, . 1. Bongani Dube, . 2. Charles Sandy, . 2. Manners Ncube, . 2 . Regina Mubau,. 2. Chlorata Gwanzura, . 2. Kwenziweyinkosi Ndlovu, .